Research ArticleBRAIN
Predictive Value of Lesions for Relapses in Relapsing-remitting Multiple Sclerosis
James A. Koziol, Simone Wagner, David F. Sobel, Lloyd S. Slivka, John S. Romine, Jack C. Sipe and Hans-Peter Adams
American Journal of Neuroradiology February 2001, 22 (2) 284-291;
James A. Koziol
Simone Wagner
David F. Sobel
Lloyd S. Slivka
John S. Romine
Jack C. Sipe
References
- ↵Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MR analysis results of a multicenter, randomized, double-blind, placebo-controlled trial: UBC MS/MR Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-667
- ↵Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3-24
- ↵Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MR in detecting disease activity in multiple sclerosis. Brain 1993;116:1077-1094
- ↵Miller DH. Guidelines for MR monitoring of the treatment of multiple sclerosis: recommendations of the US Multiple Sclerosis Society's task force. Mult Scler 1996;1:335-338
- ↵Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999;111:35-44
- ↵Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions (“black holes”) on T1 spin-echo MR correlates with disease progression in multiple sclerosis. Neurology 1996;47:1469-1476
- ↵Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-45
- ↵Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993;2:121-145
- ↵Poser CM. Exacerbations, activity, and progression in multiple sclerosis. Arch Neurol 1980;37:471-474
- Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
- Filippi M, Horsfield MA, Ader HJ, et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 1998;43:499-506
- Tofts PS. Standardisation and optimisation of magnetic resonance techniques for multicentre studies. J Neurol Neurosurg Psychiatry 1998;64:S37-S43
- ↵Barkhof F, Filippi M, van Waesberghe JH, Campi A, Miller DH, Ader HJ. Interobserver agreement for diagnostic MR criteria in suspected multiple sclerosis. Neuroradiology 1999;41:347-350
- ↵Filippi M, Rovaris M, Capra R, et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis: implications for phase II clinical trials. Brain 1998;121:2011-2020
- ↵O'Riordan J, Gawne Cain M, Coles A, et al. T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation. Mult Scler 1998;4:408-412
- Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994;344:9-13
- Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996;93:1716-1720
- ↵Koudriavtseva T, Thompson AJ, Fiorelli M, et al. Gadolinium enhanced MR predicts clinical and MR disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;62:285-287
- ↵Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging of relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 1999;353:964-969
- ↵van Walderveen MA, Truyen L, van Oosten BW, et al. Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity. Arch Neurol 1999;56:345-351
- ↵Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-440
- Miller DH. Multiple sclerosis: use of MR in evaluating new therapies. Semin Neurol 1998;18:317-325
- Molyneux PD, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MR lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998;43:332-339
- ↵Koziol JA, Wagner S, Adams HP. Assessing information in T2-weighted MR scans from secondary progressive MS patients. Neurology 1998;51:228-233
In this issue
Advertisement
Predictive Value of Lesions for Relapses in Relapsing-remitting Multiple Sclerosis
James A. Koziol, Simone Wagner, David F. Sobel, Lloyd S. Slivka, John S. Romine, Jack C. Sipe, Hans-Peter Adams
American Journal of Neuroradiology Feb 2001, 22 (2) 284-291;
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.
This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.
More in this TOC Section
Similar Articles
Advertisement